Trial ID or NCT#



recruiting iconRECRUITING


This is the first evaluation of edoxaban in pediatric subjects. In this Phase 1 study, a single dose of edoxaban will be given to pediatric subjects who require anticoagulant therapy to see what the body does to the drug (pharmacokinetics) and what the drug does to the body (pharmacodynamics), and to compare if these effects are similar to those observed in adults.

Official Title

A Phase 1, Open-Label, Single-Dose, Non-Randomized Study to Evaluate Pharmacokinetics and Pharmacodynamics of Edoxaban in Pediatric Patients

Eligibility Criteria

Ages Eligible for Study: 0 Years to 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


Michael Jeng

Contact us to find out if this trial is right for you.


Jeff Vasallo
(513) 579-9911